The two proven treatments for Guillain-Barré syndrome (GBS) are intravenous immunoglobulin (IVIG) and plasma exchange, also called plasmapheresis. Both work equally well at speeding recovery, and neither is clearly superior to the other. The choice between them often comes down to availability, the patient’s overall health, and how easily each can be administered at a given hospital. Beyond these core therapies, supportive care, pain management, and rehabilitation play major roles in how well someone recovers.
IVIG and Plasma Exchange Are Equally Effective
A systematic review and meta-analysis comparing the two treatments in patients with severe GBS found no significant difference in their ability to improve disability scores four weeks after treatment. Hospital stays, time on a ventilator, complication rates, and relapse risk were also statistically similar between the two groups.
The one notable difference: patients receiving IVIG were significantly less likely to discontinue treatment. Plasma exchange requires specialized equipment, large-bore intravenous access, and multiple sessions, which can be physically demanding. IVIG is given through a standard IV line over five consecutive days, making it simpler to administer and easier for patients to tolerate. For this practical reason, IVIG has become the more commonly used first-line treatment in many hospitals, even though the clinical outcomes are essentially the same.
How Each Treatment Works
GBS occurs when the immune system mistakenly attacks the nerves outside the brain and spinal cord. Both treatments aim to interrupt that attack, but they do it differently.
IVIG floods the body with donated antibodies at a dose of 0.4 grams per kilogram of body weight per day for five days (2 g/kg total). These donated antibodies appear to dilute and neutralize the harmful ones causing nerve damage. Plasma exchange takes a more direct approach: blood is drawn out, the liquid portion (plasma) containing the damaging antibodies is removed and replaced, and the blood cells are returned. A landmark French trial of 556 patients established that patients with moderate GBS benefit from four exchange sessions, while those with mild symptoms need only two. Adding a fifth or sixth session provided no extra benefit for severe cases beyond four.
Treatment should begin as soon as possible after diagnosis. Both therapies are most effective when started within the first two weeks of symptom onset, before nerve damage becomes extensive.
Corticosteroids Do Not Help
Despite being a go-to treatment for many autoimmune conditions, corticosteroids have no meaningful benefit in GBS. A Cochrane review of multiple trials found that corticosteroids given alone did not speed recovery or improve long-term outcomes. Oral corticosteroids actually appeared to slow recovery, with patients showing less improvement at four weeks compared to those who received no steroids at all. Intravenous corticosteroids fared slightly better but still showed no significant difference from placebo. This is one of the clearest findings in GBS research: steroids are not part of standard treatment.
A Second Course of IVIG Does Not Help Either
When patients fail to improve after a standard course of IVIG, the instinct is to give a second round. A recent randomized trial tested exactly this in patients with severe GBS and poor predicted outcomes. The second dose raised antibody levels in the blood as expected, but it did not improve clinical outcomes at all. Worse, serious side effects, including blood clots, occurred more frequently in the group that received the second course. The evidence now clearly argues against repeating IVIG one week after the first course in severe cases.
Managing Pain During GBS
Pain is one of the most underappreciated aspects of GBS. Many patients experience intense nerve pain, deep aching in the limbs, or painful tingling that can be harder to cope with than the weakness itself. Standard painkillers often fall short because this pain originates from damaged nerves rather than from tissue injury.
Gabapentin, a medication that calms overactive nerve signals, has shown the most promise. In one trial, patients taking gabapentin for seven days had pain scores roughly 3.6 points lower on a 10-point scale compared to placebo. A second trial compared gabapentin, carbamazepine (another nerve-calming drug), and placebo. Gabapentin reduced pain scores significantly from the first day. Carbamazepine took longer to kick in, with meaningful pain relief only appearing around day four, and it was less effective overall. Neither drug caused notable side effects beyond some drowsiness.
Respiratory Monitoring Is Critical
About 20 to 30 percent of GBS patients develop weakness severe enough to affect breathing. This is the most dangerous phase of the illness, and close monitoring of lung function is essential. Doctors track how much air the lungs can move with each breath. When that volume drops below a certain threshold, or when oxygen levels fall and carbon dioxide builds up, mechanical ventilation becomes necessary.
Patients with difficulty swallowing face particular risk because their airway protective reflexes may be compromised, meaning food or saliva can enter the lungs. A declining breathing capacity combined with swallowing problems is a signal that ventilation may be needed sooner rather than later. This is why many GBS patients are initially managed in an intensive care unit, even if their weakness seems moderate at first. The disease can progress rapidly over hours.
Early Rehabilitation Makes a Difference
Physical therapy should begin as early as possible, often starting from the day of hospital admission. During the acute phase, when muscles may be too weak to move voluntarily, therapy focuses on preventing joint stiffness, maintaining range of motion, and avoiding complications like blood clots and pressure sores. As strength returns, the focus shifts to standing, balance, and walking.
Case studies show meaningful gains from early, targeted rehabilitation. In one documented case, a patient who began physiotherapy on the day of admission improved from being unable to walk at all to walking with assistance within 30 days, with functional independence scores jumping from 65 out of 120 to 105 out of 120. While individual results vary widely, the principle holds: starting rehabilitation early helps avoid secondary complications and supports faster functional recovery.
What Recovery Looks Like
GBS recovery is slow and often incomplete. Even with prompt, effective treatment, 20 to 40 percent of patients cannot walk independently at six months. Most improvement happens in the first year, but nerve regrowth is a gradual process, and some patients continue to see gains for two years or longer. Residual fatigue is extremely common and can persist even after strength has largely returned.
Several factors influence prognosis. Older age, rapid onset of severe weakness, the need for mechanical ventilation, and certain subtypes of GBS that damage the nerve fibers themselves (rather than just the insulating coating) all predict a slower or less complete recovery. Patients who begin treatment early and who were otherwise healthy before the illness tend to do better.
Treatments on the Horizon
Because GBS involves the immune system’s complement cascade, a chain reaction of proteins that amplifies immune attacks, researchers are testing drugs that block this pathway. ANX005, a drug that inhibits the first step in the complement cascade, recently completed a Phase 1 trial in 50 patients. It was well tolerated with no dose-limiting side effects, and blood markers suggested it was reducing ongoing nerve damage. A larger Phase 3 trial is the next step to determine whether this translates into meaningful clinical improvement. If successful, complement inhibitors could become the first new class of GBS treatment in decades.